ACTA ENDOCRINOLOGICA (BUC)

Genetic polymorphisms play a critical role in the interindividual variability of pain perception and opioid response. These variations become relevant during pregnancy and the postpartum period, where managing pain effectively while ensuring maternal and fetal safety is a clinical priority. Polymorphisms in genes such as OPRM1, CYP2D6, COMT, UGT2B7, and ABCB1 have been linked to differences in opioid efficacy, dosing requirements, and adverse event profiles in obstetrical settings. This review synthesizes current evidence on the impact of pain-related genetic polymorphisms during labor, cesarean section, and postpartum recovery and also in onco-gynecological surgery. The article highlights the risks of under- medication or overmedication, especially in ultra-rapid and poor metabolizers, and evaluates how pharmacogenomic insights could guide safer, more personalized analgesic strategies in perinatal care and surgery, in general.

Introduction. Infertility is a very discussed problem in many endocrinological and gynecological courses and congresses. In a rapidly revolving environment women tend to postpone pregnancy to have security in their financial life and career. We discuss primary and secondary infertility and the hormonal results in women that presented for a desire to conceive with their partner. Infertility is considered to have many causes and annual follow-up is important, especially in women with no children and a stable partner.Hormonal parameters are often not recommended until late after 30 years of age, in women who adress routine consultations and should be considered much early on in their reproductive life, especially in women with familly history of premature menopause. Conclusions. There is still a lot to research in the field of ovarian response and poor ovarian reserve, but promising studies are being made in the present and near future.

Context. Infertility affects more and more younger patients nowadays. Life-saving cancer treatments - chemotherapy and radiation therapy unfortunately damage oocytes and reduce the window of fertility in women. There were an estimated 14.1 million cases of cancer worldwide in 2012, of which 6.7 million were in women. Aim. We are reviewing fertility options and treatments for women fighting oncological diseases. It is important to promote that there is a possibility for these patients to know all they can do in order to preserve their fertility and our government should help all these young patients. The trend of delayed childbearing has increased worldwide duet o increased life costs, difficulty of finding a suitable partner and carier options, while the number of women facing a cancer diagnosis is rising. Material and methods. We describe a review regarding the impact of these treatments for the fertility of these patients. Results. Show that informed patients can better cope with their diagnostic and have a better prognosis. Conclusions. Improving survival rates and current data have created a new medical field oncofertility. The term was first introduced in 2015 and is being used all over clinics that treat young patients nowadays.